Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual by Kajimura, Daisuke et al.
Article
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 208 No. 4  841-851
www.jem.org/cgi/doi/10.1084/jem.20102608
841
A notable recent advance in our understanding 
of the genetic and molecular control of bone 
remodeling has been uncovering the influence 
exerted on this process by the brain, a process 
generally referred to as the central control of bone 
mass (Karsenty, 2006). This complex, multistep 
process starts with the secretion of serotonin by 
brainstem neurons that then binds to a specific 
receptor in neurons of the ventromedial nuclei 
of the hypothalamus (Yadav et al., 2009). Sero-
tonergic signaling in these neurons leads to a 
decrease in the activity of the sympathetic ner-
vous system, which normally acts on osteoblasts 
to decrease bone formation and to increase   
osteoclast differentiation and bone resorption 
(Takeda et al., 2002; Elefteriou et al., 2004, 
2005; Fu et al., 2005).
Remarkably, and adding further complexity 
to the central control of bone mass, this entire 
regulatory loop has been shown to be under the 
control of the adipocyte-derived hormone leptin, 
which inhibits bone mass accrual by hampering 
synthesis and secretion of serotonin by brainstem 
neurons (Ducy et al., 2000; Yadav et al., 2009).   
Indeed, a cell-specific gene inactivation approach 
showed that a deletion of the leptin receptor 
in osteoblasts only does not affect bone mass   
accrual, whereas the same deletion in neurons 
recapitulates the bone phenotype observed in 
ob/ob mice (Shi et al., 2008). These data dem-
onstrate that the bulk of leptin regulation of 
bone mass accrual occurs through a neuronal 
relay, which was identified as being the sympa-
thetic tone (Takeda et al., 2002).
Previous  studies  have  established  that  the 
sympathetic tone lowers bone mass accrual by 
acting  through  the  2  adrenergic  receptor. 
These studies also identified CREB (cAMP- 
responsive element-binding protein) and cMyc 
as mediators of the sympathetic inhibition of 
proliferation and ATF4 as a mediator of its reg-
ulation of osteoclast differentiation (Elefteriou 
et al., 2005; Fu et al., 2005). Remarkably however, 
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The sympathetic nervous system, whose activity is regulated by leptin signaling in the brain, 
is a major regulator of bone mass accrual. To determine the identity of the cell type in which 
the sympathetic tone signals to inhibit bone mass accrual, we performed a systematic, cell-
specific analysis of the function of the 2 adrenergic receptor (Adr2) and various genes 
implicated in the pathway in the mouse. This was followed by leptin intracerebroventricular 
(ICV) infusion and bone histomorphometric analyses of bone parameters. We show that the 
sympathetic tone signals in the osteoblasts to inhibit CREB (cAMP-responsive element-
binding protein) phosphorylation and thus decrease osteoblast proliferation and to promote 
ATF4 phosphorylation and thus increase RANKL (receptor activator of NF-B ligand) expres-
sion, which then stimulates osteoclast differentiation. Leptin ICV infusion in various mouse 
models established that leptin-dependent inhibition of bone mass accrual relies on both 
transcriptional events taking place in osteoblasts. Thus, this study formally identifies the 
osteoblast as the major cell type in which the molecular events triggered by the sympathetic 
regulation of bone mass accrual take place. As such, it suggests that inhibiting sympathetic 
signaling could be beneficial in the treatment of low bone mass conditions.
© 2011 Kajimura et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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signaling in the brain, whose function is to decrease bone 
formation by increasing sympathetic tone (Takeda et al., 2002). 
In full agreement with this model, leptin intracerebroventric-
ular (ICV) infusion decreased CREB phosphorylation in 
control but not in Adr2osb
/ bones (Fig. 1 E). These obser-
vations indicated that the sympathetic signaling in osteoblasts 
is downstream of leptin signaling in the brain.
At the molecular level, we observed that expression of 
CyclinD1, CyclinD2, CyclinE1, cMyc, and Per1, all genes impli-
cated in the sympathetic regulation of bone mass accrual 
(Fu et al., 2005), was significantly increased in Adr2osb
/ 
bones (Fig. 1 F). Similarly, the expression of Cry1 and Cry2 
was increased (Fig. S2 A). In contrast, the ratio of Rankl to 
Opg expression was decreased (Fig. 1 G). Based on these re-
sults, we anticipated that leptin ICV infusion, a procedure 
which decreases bone mass by decreasing bone formation pa-
rameters and increasing bone resorption parameters in WT 
mice, should fail to do so in Adr2osb
/ mice. That is exactly 
what was observed in 12-wk-old Adr2osb
/ mice (Fig. 1, I–M). 
In summary, the analysis of mice lacking Adr2 only in   
osteoblasts established that the sympathetic tone lowers bone 
mass accrual by signaling in osteoblasts through the Adr2. 
The clarity of the effect (and lack) of leptin ICV infusion in 
WT (and Adr2osb
/ mice) led us to use this assay as a tool 
to verify in the rest of the study the cell-specific nature of 
other aspects of the leptin/sympathetic regulation of bone 
mass accrual.
Leptin inhibition of bone mass accrual requires Creb 
expression in osteoblasts
Previous experiments have suggested that the sympathetic 
tone acts, in osteoblasts, through CREB to regulate bone for-
mation and that leptin signaling in the brain affects this pro-
cess (Fu et al., 2005). To determine whether it is indeed the 
case, we generated, using the aforementioned strategy, mice 
lacking CREB in osteoblasts only (Crebosb
/ mice) and, as we 
did in all experiments, verified that we had achieved an effi-
cient and cell-specific gene deletion before using these mu-
tant mice (Fig. 2, A and B).
CREB has recently emerged as a more important than 
anticipated positive transcriptional regulator of bone forma-
tion (Yadav et al., 2008, 2009; Datta and Abou-Samra, 2009; 
Oury et al., 2010). In particular, it has been shown to be a 
transcriptional effector of the anabolic action of parathyroid 
hormone (Datta and Abou-Samra, 2009), while its function is 
inhibited by gut-derived serotonin, which is a negative regu-
lator of bone formation (Yadav et al., 2008). Given the exis-
tence of these two important regulations, it is no surprise that 
at 12 wk of age, Crebosb
/ mice display low bone mass be-
cause of an isolated decrease in bone formation parameters 
(Fig. 2 C). Nevertheless, to determine whether CREB is a 
transcriptional mediator of the sympathetic tone-dependent 
regulation of bone formation, we studied the expression of 
genes regulated by the sympathetic tone in Crebosb
/ bones. 
As was the case in Adr2osb
/ bones, expression of genes 
implicated in the sympathetic regulation of bone formation, 
until now, the identity of the cell in which the sympathetic 
tone acts to inhibit bone mass accrual has remained elusive. 
The reason for this ambiguity is that no cell-specific gene de-
letion of the 2 adrenergic receptor (Adr2) experiments 
have been reported yet (Elefteriou et al., 2005; Fu et al., 2005). 
This is obviously an important question, as the nature of the 
sympathetic target cells ultimately defines how leptin regu-
lates bone mass accrual.
To address this important lingering issue regarding the   
peripheral mediation of the central control of bone mass, we 
have embarked on a systematic, cell-specific analysis of the 
aforementioned key molecular players. This analysis demon-
strates that Adr2, Creb, and cMyc and Atf4 act in osteoblasts 
to control osteoblast proliferation and osteoclast differentia-
tion, respectively, and that this pathway is influenced by leptin. 
As such, this study provides a more complete understanding 
of the central control of bone mass and opens a new thera-
peutic avenue for low bone mass diseases.
RESULTS
Adr2 regulates bone mass accrual through its expression 
in osteoblasts
To identify the cell type in which the sympathetic nervous 
system acts to regulate bone mass accrual, we relied on cell-
specific gene inactivation in the mouse. To determine whether 
the sympathetic tone signals in osteoblasts to regulate bone 
mass accrual, we generated a mutant mouse strain expressing 
a floxed allele of Adr2, the adrenergic receptor whose deletion 
in all cells affects bone mass accrual (Elefteriou et al., 2005). 
These mutant mice were crossed with 1(I) Collagen (2.3-kb 
Col1a1 promoter)–Cre transgenic mice to delete the gene in 
osteoblasts only (Adr2osb
/ mice; Dacquin et al., 2002). Before 
analyzing the mutant mice, we verified that we had achieved 
a high percentage of recombination at the Adr2 locus in   
osteoblasts but in no other cell types (Fig. 1, A and B).
As it is the case in mice lacking Adr2 in all cells (Elefteriou 
et al., 2005), Adr2osb
/ mice had a normal bone mass until 
12 wk of age (Fig. 1 L). However, at 24 wk of age, Adr2osb
/ 
mice presented a distinct high bone mass phenotype affecting 
both vertebrates and long bones (Fig. 1, C and D), whose se-
verity was similar to the one observed in mice lacking Adr2 
in all cells. Histomorphometric analysis of vertebrae showed 
that this high bone mass phenotype was caused by a concom-
itant increase in the number of osteoblasts and bone formation 
rate (BFR) and a decrease in the osteoclast number (Fig. 1 C). 
As expected, the decrease in osteoclast number did result 
in a decrease in bone resorption activity, as determined by   
serum levels of carboxy-terminal cross-linking telopeptide of 
type I collagen (CTx), which was decreased in Adr2/ 
mice (Fig. 1 H). These results established that the osteoblast is 
a major target of the sympathetic tone regulation of bone 
mass accrual.
Our previously published work (Fu et al., 2005) has estab-
lished that the sympathetic tone in osteoblasts regulates phos-
phorylation of CREB on serine 133 and of ATF4 on serine 
254. Moreover, these two events should be altered by leptin JEM VOL. 208, April 11, 2011 
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Figure 1.  Analysis of Adr2osb
/ mice. (A) Specificity of 1(I) Collagen–Cre-driven deletion of Adr2 allele in bone. (B) Expression level of Adr2 protein in bone 
marrow–derived osteoblasts. (C) Bone histomorphometric analysis Adr2osb
/ mice at 24 wk of age (control, n = 11; Adr2osb
/, n = 7). Mineralized bone matrix is 
stained in black by Von Kossa reagent. Histomorphometric parameters: BV/TV, bone volume over tissue volume; Ob.Nb/T.Ar, number of osteoblasts per trabecular area; 
Oc.S/T.Ar, osteoclast surface per trabecular area. (D) µCT analysis of control (n = 6) and Adr2osb
/ (n = 5) proximal tibiae at 24 wk of age. Ct.Th, cortical thickness.  
(E) Expression of phospho-CREB and total CREB after 28-d leptin ICV infusion at 12 wk of age. (F and G) Expression of various genes in control (n = 7) and Adr2osb
/ 
(n = 7) bone at 24 wk of age. (H) Serum CTx levels of control (n = 8) and Adr2osb
/ (n = 7) mice at 24 wk of age. (I–L) Bone histomorphometric analysis of 12-wk-old 
Adr2osb
/ mice after leptin ICV infusion shown as percentage compared with control mice treated with vehicle ICV infusion (control mice with vehicle ICV infusion, 
n = 9; control mice with leptin ICV infusion, n = 8; Adr2osb
/ mice with vehicle ICV infusion, n = 5; Adr2osb
/ mice with leptin ICV infusion, n = 5). (M) Bone histo-
morphometric analysis of 12-wk-old Adr2osb
/ mice after leptin ICV infusion. All experiments were performed independently at least twice, and representative data 
are shown. Results are shown as mean ± SEM. Statistical analysis was performed by Student’s t test. For all panels: *, P < 0.05.844 Sympathetic control of bone mass via osteoblasts | Kajimura et al.
Figure 2.  Analysis of Crebosb
/ mice. (A) Specificity of 1(I) Collagen–Cre-driven deletion of Creb allele in bone. (B) Expression level of the CREB protein 
in bone marrow–derived osteoblasts. (C) Bone histomorphometric analysis of Crebosb
/ mice at 12 wk of age (control, n = 14; Crebosb
/, n = 12). BV/TV, bone 
volume over tissue volume; Ob.Nb/T.Ar, number of osteoblasts per trabecular area; Oc.S/T.Ar, osteoclast surface per trabecular area. (D) µCT analysis of control 
(n = 5) and Crebosb
/ (n = 5) proximal tibiae at 12 wk of age. (E and F) Expression of various genes in control (n = 7) and Crebosb
/ (n = 3) bone at 12 wk of 
age. (G) Serum CTx levels of control (n = 7) and Crebosb
/ (n = 7) mice at 12 wk of age. (H–K) Bone histomorphometric analysis of Crebosb
/ mice after leptin 
ICV infusion at 12 wk of age shown as percentage compared with control mice with vehicle ICV infusion (control mice with vehicle ICV infusion, n = 14;  
control mice with leptin ICV infusion, n = 12; Crebosb
/ mice with vehicle ICV infusion, n = 8; Crebosb
/ mice with leptin ICV infusion, n = 10). (L) Bone  
histomorphometric analysis of 12-wk-old Crebosb
/ mice after leptin ICV infusion. All experiments were performed independently at least twice, and  
representative data are shown. Results are shown as mean ± SEM. Statistical analysis was performed by Student’s t test. For all panels: *, P < 0.05.JEM VOL. 208, April 11, 2011 
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CyclinD1, CyclinD2, CyclinE1, Per1, and cMyc, was affected 
in Crebosb
/ bones (Fig. 2 E). Consistent with the decreased 
expression of cell cycle regulator genes, osteoblast prolifera-
tion, as measured by BrdU incorporation, was markedly re-
duced in Crebosb
/ bones (Fig. S2 B). In contrast, the ratio of 
Rankl to Opg expression and bone resorption measured by 
serum CTx levels were not affected (Fig. 2, F and G). Thus, 
CREB, through its expression in osteoblasts, regulates osteo-
blast proliferation.
Next, we asked whether leptin signaling ultimately re-
quires Creb expression in osteoblasts to inhibit bone mass ac-
crual. As shown in Fig. 2 (H, I, and L), long-term leptin ICV 
infusion failed to decrease bone formation parameters, although 
it could increase osteoclast number in Crebosb
/ mice (Fig. 2,   
J and L). As a result, leptin ICV infusion decreased, albeit 
mildly, bone volume in Crebosb
/ mice (Fig. 2, K and L).
The fact that leptin ICV infusion could decrease bone 
volume in Crebosb
/ mice can be explained only if one hypoth-
esizes that the sympathetic tone can increase bone resorption 
independently from CREB, possibly through ATF4. If it is the 
case, one would expect that by deleting Creb in osteoblasts, 
one would blunt the inhibition of bone formation induced 
by the sympathetic tone, without affecting bone resorption.
Leptin regulation of bone resorption requires Atf4 
expression in osteoblasts
If the aforementioned explanation of the bone phenotype of 
Crebosb
/ mice and of the influence that leptin exerts on it is 
correct, it could be verified through the use of mice lacking 
Atf4 in osteoblasts only (Fig. 3). As is the case in mice lacking 
Atf4 in all cells, Atf4osb
/ mice have a low bone mass pheno-
type caused by a decrease in bone formation parameters 
(Fig. 3 C; Yang et al., 2004; Elefteriou et al., 2006). The de-
crease in bone formation parameters could be explained, at 
least in part, by an alteration in osteoblast differentiation be-
cause expression of two ATF4 target genes, Bglap1 and Col1a1, 
was significantly reduced in Atf4osb
/ bone (Fig. S2 C). 
On the contrary, unlike what is the case in Adr2osb
/ and 
Crebosb
/ mice, expression of cell cycle regulator genes 
CyclinD1, CyclinD2, CyclinE1, Per1, and cMyc was not affected 
(Fig. 3 E). These results are consistent with the hypothesis that 
the expression of these genes in osteoblasts is under the control 
of CREB, not ATF4 (Fig. 2; Fu et al., 2005). In contrast, the 
ratio of Rankl to Opg expression was lower in Atf4osb
/ mice 
(Fig. 3 F). To formally verify our hypothesis, we then infused 
leptin ICV in control and Atf4osb
/ mice. Leptin ICV infusion 
increased the osteoclast number in control but not in Atf4osb
/ 
mice (Fig. 3, J and L). However, this procedure decreased bone 
formation in both control and mutant mice. This was ex-
pected because CREB signaling is intact in Atf4osb
/ bones. 
That leptin ICV infusion could decrease bone formation pa-
rameters (Fig. 3, H, I, and L) explains also why it could de-
crease bone mass on Atf4osb
/ mice (Fig. 3, K and L).
Collectively, the analysis of cell-specific gene inactivation 
mouse models for two distinct transcription factors presented 
in Figs. 2 and 3 suggested a model whereby the sympathetic 
tone uses CREB and ATF4 in osteoblasts to influence bone 
formation and bone resorption, respectively (Fig. S1).
Leptin inhibition of bone mass accrual requires cMyc 
expression in osteoblasts
We have shown earlier that downstream of the sympathetic 
regulation of bone formation, cMyc must be a target of CREB 
(Fu et al., 2005). To determine whether cMyc carries out this 
function through its expression in osteoblasts, we used the 
same strategy used for the study of Adr2 and Creb and Atf4 
functions in osteoblasts (Figs. 1–3) and again verified before 
using them that we had achieved an efficient and osteoblast-
specific deletion in cMycosb
/ mice (Fig. 4, A and B).
We should emphasize here that unlike other mutant mice, 
cMycosb
/ mice were maintained on a mixed genetic back-
ground including C57/B6 and 129Sv/EV. This difference in 
genetic background explains the rather high bone volume 
observed in control cMyc-flox/flox and mutant cMycosb
/ 
littermates compared with other mutant mice that were all 
on a pure C57/B6 background (Fig. 4 C). Notwithstanding 
this feature, and when compared with cMyc-flox/flox mice, 
cMycosb
/ mice demonstrated a low bone mass phenotype at 
12 wk of age that was secondary to a decrease in bone forma-
tion parameters (Fig. 4 C). The osteoclast number and activity 
were not significantly affected in cMycosb
/ mice (Fig. 4,   
C and G). Consistent with the notion that cMyc may be a target 
gene of the sympathetic tone and CREB in osteoblasts, ex-
pression of the cyclin genes CyclinD1, CyclinD2, and CyclinE1 
was also significantly decreased in cMycosb
/ bones (Fig. 4 E). 
In contrast, the expression ratio of Rankl to Opg was not af-
fected (Fig. 4 F). The expression of Opg was not affected in 
cMycosb
/ bones (Fig. S3, A–D).
To determine formally that leptin inhibition of bone mass 
accrual requires the expression of cMyc in osteoblasts, we per-
formed long-term leptin ICV infusion in control and cMycosb
/ 
mice. As shown in Fig. 4 (H, I, and L), leptin ICV infusion 
decreased bone formation parameters in control but not in 
cMycosb
/ mice. In contrast, and in full agreement with the ATF4 
mediation of this aspect of the regulation of bone mass accrual, 
leptin  ICV  infusion  increased  bone  resorption  parameters 
equally well in control and in cMycosb
/ mice (Fig. 4, J and L). 
As a result, leptin decreased bone mass in both control and in 
cMycosb
/ mice, although the effect was more pronounced   
in control mice (Fig. 4, K and L).
Genetic interaction between Adr2, Creb, and cMyc 
expression in osteoblasts downstream of leptin signaling
In the last part of these experiments, we sought to establish 
that the leptin regulation of bone mass accrual requires the 
various transcription factors studied in this paper to interact 
in the osteoblasts. This is a particularly important aspect of our 
work because CREB, for instance, can be activated by a protein 
kinase A–dependent but also by other, unrelated pathways.
Consistent with the notion that cMyc is a downstream 
target gene of CREB, cMycosb
/ mice showed a similar pheno-
type as Crebosb
/ mice as well as a similar response to long-term 846 Sympathetic control of bone mass via osteoblasts | Kajimura et al.
Figure 3.  Analysis of Atf4osb
/ mice. (A) Specificity of 1(I) Collagen–Cre-driven deletion of Atf4 allele in bone. (B) Expression level of the ATF4 pro-
tein in bone. (C) Bone histomorphometric analysis of Atf4osb
/ mice at 12 wk of age (control, n = 10; Atf4osb
/, n = 9). BV/TV, bone volume over tissue 
volume; Ob.Nb/T.Ar, number of osteoblasts per trabecular area; Oc.S/T.Ar, osteoclast surface per trabecular area. (D) µCT analysis of control (n = 5) and 
Atf4osb
/ (n = 5) proximal tibiae at 12 wk of age. (E and F) Expression of various genes in control (n = 9) and Atf4osb
/ (n = 9) bone at 12 wk of age.  
(G) Serum CTx levels of control (n = 8) and Atf4osb
/ mice (n = 8) at 12 wk of age. (H–K) Bone histomorphometric analysis of Atf4osb
/ mice after leptin 
ICV infusion at 12 wk of age shown as percentage compared with control mice treated with vehicle ICV infusion (control mice with vehicle ICV infusion,  
n = 10; control mice with leptin ICV infusion, n = 9; Atf4osb
/ mice with vehicle ICV infusion, n = 9; Atf4osb
/ mice with leptin ICV infusion, n = 9).  
(L) Bone histomorphometric analysis of 12-wk-old Atf4osb
/ mice after leptin ICV infusion. All experiments were performed independently at least twice, 
and representative data are shown. Results are shown as mean ± SEM. Statistical analysis was performed by Student’s t test. For all panels: *, P < 0.05.JEM VOL. 208, April 11, 2011 
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Figure 4.  Analysis of cMycosb
/ mice. (A) Specificity of 1(I) Collagen–Cre-driven deletion of cMyc allele in bone. (B) Expression level of the cMyc protein 
in bone marrow–derived osteoblasts. (C) Bone histomorphometric analysis of cMycosb
/ mice at 12 wk of age (control, n = 14; cMycosb
/, n = 9). BV/TV, 
bone volume over tissue volume; Ob.Nb/T.Ar, number of osteoblasts per trabecular area; Oc.S/T.Ar, osteoclast surface per trabecular area. (D) µCT analysis of 
control (n = 5) and cMycosb
/ (n = 5) proximal tibiae at 12 wk of age. (E and F) Expression of various genes in control (n = 3) and cMycosb
/ (n = 7) bone at 
12 wk of age. (G) Serum CTx levels of control (n = 6) and cMycosb
/ (n = 6) at 12 wk of age. (H–K) Bone histomorphometric analysis of cMycosb
/ mice after 
leptin ICV infusion at 12 wk of age shown as percentage compared with control mice treated with vehicle ICV infusion (control mice with vehicle ICV infusion, 
n = 14; control mice with leptin ICV infusion, n = 8; cMycosb
/ mice with vehicle ICV infusion, n = 9; cMycosb
/ mice with leptin ICV infusion, n = 10).  
(L) Bone histomorphometric analysis of 12-wk-old cMycosb
/ mice after leptin ICV infusion. All experiments were performed independently at least twice, 
and representative data are shown. Results are shown as mean ± SEM. Statistical analysis was performed by Student’s t test. For all panels: *, P < 0.05.848 Sympathetic control of bone mass via osteoblasts | Kajimura et al.
leptin ICV infusion. To verify in vivo that these genes are in 
the same pathway downstream of leptin signaling in osteoblasts, 
we generated Crebosb
+/;cMycosb
+/ compound heterozygous 
mice. That Crebosb
+/;cMycosb
+/ mice had decreased bone for-
mation parameters, while bone resorption parameters were 
not affected (Fig. 5, A–E), supports the notion that both Creb 
and cMyc regulate osteoblast proliferation in osteoblasts but 
not osteoclast differentiation.
Next, we asked whether the high bone mass phenotype of 
the Adr2osb
/ mice could be corrected by removing one 
copy of cMyc in osteoblasts. As shown in Fig. 5 (F–J) and Fig. S4, 
removing one allele of cMyc in osteoblasts normalized bone 
formation parameters in Adr2osb
/ mice. In contrast, this ma-
nipulation did not affect the bone resorption parameters in 
Adr2osb
/ mice, further indicating that the sympathetic tone 
uses different transcriptional mediators to regulate bone forma-
tion and bone resorption. Thus, the analysis of these compound 
mutant mouse strains verified the existence of an interaction 
between Adr2, Creb, and cMyc in the osteoblast to allow the 
sympathetic nervous system to prevent bone mass accrual.
Figure 5.  Genetic epistasis analysis. (A–E) Bone histomorphometric analysis of Crebosb
+/;cMycosb
+/ mice at 12 wk of age (controls, n = 15; Crebosb
+/,  
n = 9; cMycosb
+/, n = 4; Crebosb
+/;cMycosb
+/, n = 8). (F–J) Bone histomorphometric analysis of Adr2osb
/;cMycosb
+/ mice at 24 wk of age (controls, n = 11; 
Adr2osb
/, n = 7; Adr2osb
/;cMycosb
+/, n = 9). *, P < 0.05 between controls; **, P < 0.05 between Adr2osb
/ mice and Adr2osb
/;cMycosb
+/ mice. Ex-
periments were performed independently twice, and representative data are shown. Results are shown as mean ± SEM. Dashed lines indicate control value of 
100%. BV/TV, bone volume over tissue volume; Ob.Nb/T.Ar, number of osteoblasts per trabecular area; Oc.S/T.Ar, osteoclast surface per trabecular area.JEM VOL. 208, April 11, 2011 
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this function of the sympathetic nervous system, leptin. Indeed, 
long-term ICV infusion of this hormone in mutant mice 
lacking, in osteoblasts only, either Creb or Atf4 verified that 
leptin and the sympathetic tone recruit each of these two 
transcription factors for different purposes.
Looking more globally at these regulations of bone mass 
by leptin, it underscores the importance of the various roles 
played by CREB at several steps in this pathway. Indeed, CREB 
is mediating serotonin regulation of the sympathetic tone in 
the ventromedial hypothalamic nuclei, a regulation inhibited 
by leptin signaling in the brain. Thus, CREB acts upstream of 
the sympathetic tone (Oury et al., 2010). The present study 
shows that it also acts downstream of it and in osteoblasts.
This work, by showing that the bulk of the sympathetic 
regulation of bone mass accrual occurs in osteoblasts, raises the 
question of its pharmacological relevance. The work of Bonnet 
et al. (2008) showing that a low dose of  blockers acting 
through Adr2 could prevent gonadectomy-induced bone loss 
without affecting other function regulated by the sympathetic 
nervous system is in full agreement with the fact that mice lack-
ing only one allele of Adr2 display high bone mass. As such,   
it is certainly important if this pathway could be exploited fur-
ther for the purpose of treating low bone mass disease.
MATERIALS AND METHODS
Animals. Adr2osb
/, Crebosb
/, Atf4osb
/, cMyc-flox/flox, and 1(I) Colla-
gen (2.3-kb Col1a1 promoter)–Cre mice were previously described (de Alboran 
et al., 2001; Dacquin et al., 2002; Hinoi et al., 2008; Couillard and Trudel, 
2009; Yoshizawa et al., 2009). cMyc-flox/flox mice were provided by F.W. Alt 
(Harvard Medical School, Boston, MA) and M. Trudel (Université de Mon-
tréal, Montréal, Québec, Canada), and Creb-flox/flox mice were provided by 
G. Schütz (German Cancer Research Center, Heidelberg, Germany). Adr2-
flox/flox,  Creb-flox/flox,  Atf4-flox/flox,  and  cMyc-flox/flox  littermates  were   
used  for  the  control  mice  for  Adr2osb
/,  Crebosb
/,  Atf4osb
/,  and   
cMycosb
/ mice, respectively. For Crebosb
+/;cMycosb
+/mice analysis, Creb-
flox/+;cMyc-flox/+ mice were used as controls. Crebosb
+/ mice, Creb-flox/+, 
cMycosb
+/ mice, and cMyc-flox/+ mice were independently analyzed. For 
Adr2osb
/;cMycosb
+/ mice analysis, Adr2-flox/flox;cMyc-flox/+ mice were 
used as control. For Adr2osb
/ mice, Adr2-flox/flox mice were used as 
control. cMycosb
+/ mice and cMyc-flox/+ mice were independently analyzed. 
Genotyping was performed by PCR analysis of genomic DNA. All mutant 
mouse strains were on C57BL6/J except cMycosb
/ mice, which are on 
C57BL6/J and 129Sv/EV. All procedures involving animals were approved 
by the Columbia University the Institutional Animal Care and Use Commit-
tee and conform to the relevant regulatory standards.
Cell culture. Bone marrow–derived osteoblasts were prepared as previously 
described (Takahashi et al., 1988; Ferron et al., 2010). In brief, mice were sac-
rificed at the age of 2–3 wk. Bone marrow from tibia was flushed out with 
PBS, and cells were plated at 0.4 million cells/cm2 in -MEM containing 
15% FBS. 4 d after plating cells, medium was replaced by -MEM containing 
10% FBS, 5 mM -glycerophosphate, 100 µg/ml ascorbic acid, and 10 nM 
dexamethasone and cultured for 7 d. Medium was changed every other day.
Bone histomorphometric analysis. Bone histomorphometry was per-
formed as previously described (Chappard et al., 1987; Parfitt et al., 1987).   
In brief, lumbar vertebrae were dissected, fixed for 24 h in 10% formalin, de-
hydrated in graded ethanol series, and embedded in methyl methacrylate 
resin according to standard protocols. Von Kossa/Von Gieson staining was 
performed using 7-µm sections for bone volume over tissue volume mea-
surement. BFR was analyzed by the calcein double labeling method. Calcein 
(Sigma-Aldrich) was dissolved in calcein buffer (0.15 M NaCl and 2% NaHCO3) 
DISCUSSION
In this study, we used genetic and pharmacological means to 
formally identify the osteoblast as the major cell type in which 
the sympathetic tone, under the control of leptin signaling in 
the brain, acts to inhibit bone mass accrual. Results of this in-
vestigation are represented schematically in Fig. S1. We can-
not exclude, based on our results, the possibility that osteocytes 
may also be a target of the sympathetic tone. We should em-
phasize here that our study is restricted to the means whereby 
leptin signaling in the brain, as represented by leptin ICV in-
fusion, regulates bone mass. The reason for this focus on this 
aspect of leptin regulation of bone mass accrual is that a neuron-
specific inactivation of the leptin receptor in the mouse 
recapitulates the bone phenotype of mice lacking leptin sig-
naling, whereas its osteoblast-specific inactivation fails to do 
so (Shi et al., 2008).
Once it was realized that there was a central control of 
bone mass (Ducy et al., 2000), the next question was to deci-
pher how the brain signals to the bone. It became rapidly 
apparent that the sympathetic nervous system is a critical me-
diator of this homeostatic function exerted by the brain. This 
signaling inhibits bone mass accrual by, at the same time, pre-
venting bone formation and favoring bone resorption. The 
evidence supporting this view was genetic and relied on the 
study of a classical gene inactivation mouse model. Indeed, 
mice lacking the 2 adrenergic receptor in all cells had a high 
bone mass secondary to an increase in osteoblast proliferation 
and bone formation and a subsequent decrease in bone re-
sorption (Elefteriou et al., 2005). It was also supported by a 
clinical aspect such as the low bone mass of patients affected 
with reflex sympathetic dystrophy (Schwartzman, 2000).
Several transcription factors have been implicated in me-
diating this function of the sympathetic tone, and it has long 
been assumed, although never tested, that this regulation takes 
place in the osteoblasts (Elefteriou et al., 2005, 2006; Fu et al., 
2005).  However,  because  many  of  these  molecular  players 
such as Adr2, CREB, and cMyc are by no means osteoblast-
specific molecules, there was an urgent need to demonstrate 
that indeed it is in osteoblasts that this pathway operates. What 
the experiments presented in this study establish is that it is by 
acting in the osteoblasts that the sympathetic tone regulates 
bone mass accrual. It is also through its expression in osteo-
blasts  that  CREB  regulates  osteoblast  proliferation  down-
stream of the sympathetic tone. Likewise, it is through its 
expression in osteoblasts that ATF4 favors Rankl expression 
and osteoclast differentiation downstream of the sympathetic 
tone. It is noteworthy that these two transcription factors 
have distinct functions. Indeed, CREB regulates osteoblast 
proliferation  but  does  not  affect  osteoclast  differentiation, 
whereas ATF4 affects osteoclast differentiation but is not in-
volved in osteoblast proliferation.
In considering the overall sympathetic mode of regulating 
bone mass accrual, it is quite remarkable that the sympathetic 
tone recruits two different transcription factors in the same 
cell to regulate each arm of bone remodeling. Remarkably, this 
specificity is conserved when one looks at the main regulator of 850 Sympathetic control of bone mass via osteoblasts | Kajimura et al.
Online supplemental material. Fig. S1 shows a schematic representation 
of the peripheral mediation of the leptin-dependent sympathetic regulation 
of bone mass accrual. Fig. S2 shows gene expression and BrdU incorporation 
analysis. Fig. S3 shows Opg expression in Adr2osb
/, Crebosb
/, Atf4osb
/, 
and  cMycosb
/  mice.  Fig.  S4  shows  bone  histomorphometric  analysis  of   
cMycosb
+/ mice. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20102608/DC1.
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